Overview

Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.

Phase:

Phase 4

Details

Lead Sponsor:

Peking University

Treatments:

Entecavir